Semaglutide for MASH: why ESSENCE reported two biopsy answers

The question

ESSENCE's interim results answered two related liver-biopsy questions: whether steatohepatitis resolved without worsening fibrosis, and whether fibrosis improved without worsening steatohepatitis. These are not interchangeable definitions of a “healthy liver,” and neither should be rewritten as proof that every future liver complication was prevented.

That distinction is especially useful now that Wegovy injection has a US MASH indication. The evidence and the regulatory decision can be explained clearly without turning either into a universal claim about every semaglutide product.

What the 72-week analysis included

The phase 3 trial enrolled 1,197 people with biopsy-defined MASH and stage 2 or 3 fibrosis, randomized to semaglutide or placebo. The planned interim analysis reported the first 800 participants at week 72; the trial design extends to 240 weeks. Novo Nordisk funded the study. Original ESSENCE abstract.

Keep “interim” attached to the result. It does not make the finding unimportant, but it tells us which part of a longer research program has been reported. The ESSENCE registry is the appropriate place to track the study record rather than assuming that publication of part one ends every remaining question.

The population also matters. A study in biopsy-defined MASH with particular fibrosis stages cannot automatically answer the same question for someone with an isolated abnormal liver test, uncomplicated liver fat or cirrhosis.

Two endpoints, two safeguards

Steatohepatitis resolution without worsening fibrosis occurred in 62.9% with semaglutide and 34.3% with placebo. Fibrosis reduction without worsening steatohepatitis occurred in 36.8% and 22.4%. The reported treatment differences were 28.7 and 14.4 percentage points, respectively. Primary biopsy results.

The phrase “without worsening” is doing real work. Improvement in one feature was not enough if the other specified feature deteriorated. Omitting that condition makes the endpoint easier to say but less accurate.

A useful way to read the two answers is as separate gates. Passing the inflammation-related gate does not automatically mean passing the fibrosis gate. Conversely, improvement in fibrosis is not the same statement as resolution of steatohepatitis. The article reports a separate combined response; it should not be inferred by multiplying the two headline percentages.

For a hypothetical example, imagine 100 people assessed on two criteria. Some could meet both, some only one and some neither. Knowing each criterion's percentage alone does not tell us the overlap. That is a property of the data, not something a reader can safely guess.

Biopsy change and future clinical events

These interim findings concern liver histology—the assessed tissue features. A claim about avoiding a transplant, preventing decompensation or extending life requires the corresponding clinical-outcome evidence. A favorable biopsy result should retain its original endpoint rather than being promoted to a different result in a marketing sentence.

This does not mean that histology lacks value. It means the evidence should be described at the level actually measured. The distinction is similar to a school measuring progress on a skills assessment: an informative result can matter without being every later outcome at once.

Our survodutide MASH explainer discusses another compound's study. Different protocols and populations prevent a simple ranking by whichever percentage looks larger. Direct comparisons require an appropriate comparative design.

What accelerated approval means here

FDA announced the Wegovy injection MASH approval in August 2025. The corresponding label covers adults with noncirrhotic MASH and moderate-to-advanced fibrosis, consistent with stages F2–F3. It identifies accelerated approval based on improvement in MASH and fibrosis, with continued approval potentially contingent on verification and description of clinical benefit. FDA announcement and approval label.

Accelerated approval is approval for the specified medicine and use. It is also a reason to preserve the distinction between the supporting endpoint and confirmation of clinical benefit. Neither “not really approved” nor “all long-term questions settled” describes that framework accurately.

Gastrointestinal adverse events were more common with semaglutide in ESSENCE. Trial safety summary. This article is not a complete safety review or a treatment recommendation. The approved product's warnings and an individual's clinical circumstances remain part of a medical decision.

Our compounded semaglutide guide explains why an ingredient name does not establish equivalence to a finished approved medicine. A research-material listing is further removed: the biopsy results do not validate that listing's contents or clinical use.